Vicriviroc
Vicriviroc (SCH 417690) is an orally active CCR5 antagonist with the IC50 of 10 nM, and also inhibts MIP-1α and intracellular calcium release induced by the ligand RANTES (10 nM) with the IC50 values of 0.91 nM and 16 nM,,respectively. Vicriviroc can inhibits human immunodeficiency virus type 1 (HIV-1) infection, and can also used for study of cancer.
For research use only. We do not sell to patients.
- CAS No.: 306296-47-9
- Formula: C28H38F3N5O2
- Molecular Weight:533.63
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MT4 | CC50 |
>5 μM
Compound: SCH-D
|
Cytotoxicity against human MT4 cells by MTT assay
Cytotoxicity against human MT4 cells by MTT assay
|
[PMID: 26094944] |
| MT4 | CC50 |
>5 μM
Compound: SCH-D
|
Cytotoxicity against human MT4 cells by MTT assay in presence of 5 uM of chloroquine
Cytotoxicity against human MT4 cells by MTT assay in presence of 5 uM of chloroquine
|
[PMID: 26094944] |
| MT4 | CC50 |
>5 μM
Compound: SCH-D; Sch-417690
|
Cytotoxicity against Human immunodeficiency virus 1 NL4-3 infected in human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay
Cytotoxicity against Human immunodeficiency virus 1 NL4-3 infected in human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay
|
[PMID: 32305183] |
| MT4 | CC50 |
>5 μM
Compound: SCH-D; Sch-417690
|
Cytotoxicity against in human MT-4 after 5 days by MTT assay
Cytotoxicity against in human MT-4 after 5 days by MTT assay
|
[PMID: 33316719] |
| MT4 | EC50 |
>5 μM
Compound: SCH-D
|
Antiviral activity against T-cell line-tropic HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay
Antiviral activity against T-cell line-tropic HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay
|
[PMID: 26094944] |
| MT4 | EC50 |
>5 μM
Compound: SCH-D
|
Antiviral activity against T-cell line-tropic HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay in presence of 5 uM of chloroquine
Antiviral activity against T-cell line-tropic HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay in presence of 5 uM of chloroquine
|
[PMID: 26094944] |
| PBMC | IC50 |
0.23 nM
Compound: Sch-D
|
Antiviral activity against HIV-1 BaL infected in PHA-stimulated human PBMC cells assessed as viral p24 core protein level after 7 days by ELISA
Antiviral activity against HIV-1 BaL infected in PHA-stimulated human PBMC cells assessed as viral p24 core protein level after 7 days by ELISA
|
[PMID: 24900235] |
| PBMC | IC50 |
0.56 nM
Compound: Sch-D
|
Antiviral activity against HIV-1 ADA infected in PHA-stimulated human PBMC cells assessed as viral p24 core protein level after 7 days by ELISA
Antiviral activity against HIV-1 ADA infected in PHA-stimulated human PBMC cells assessed as viral p24 core protein level after 7 days by ELISA
|
[PMID: 24900235] |
| PBMC | IC50 |
1.2 nM
Compound: Sch-D
|
Antagonist activity at CCR5 in IL-10 stimulated human PBMC cells assessed as MIP-1beta induced chemotaxis
Antagonist activity at CCR5 in IL-10 stimulated human PBMC cells assessed as MIP-1beta induced chemotaxis
|
[PMID: 24900235] |
Chemical Information
-
CAS No. 306296-47-9
-
Molecular Weight 533.63
-
Formula C28H38F3N5O2
-
SMILES
COC[C@@H](C1=CC=C(C=C1)C(F)(F)F)N2[C@H](CN(C3(CCN(CC3)C(C4=C(C)N=CN=C4C)=O)C)CC2)C
-
Synonyms
SCH 417690; SCH-D; MK-7690 free base
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Strizki JM, et al. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2005;49(12):4911-4919. [Content Brief]
[2]. Bessudo A, et al. Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab in Patients With Advanced or Metastatic Microsatellite Stable Colorectal Cancer. Clin Colorectal Cancer. 2024;23(3):285-294. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)